I am going to go out and have all these town hall meetings, and I am going to hold that up.

Your bill with Senator Grassley should make it more difficult for PBMs to hide profits from regulators.

People care a whole lot about this matter of getting mugged at the pharmacy counter.

I am leading a bill with Senator Grassley, the Pharmacy Benefit Manager Transparency Act, which would crack down on PBM's opaque rebate practices.

We want to make this a bipartisan effort in this committee.

The problem is that the person negotiating on behalf of the patient should not be getting paid by the other side.

Our bipartisan efforts on organ transplants--thank you very much, Senator Grassley--have really paid off.

In my view, that's a clear example of the perverse incentives PBMs have created that leave so many Americans fed up and outraged at the health-care system in this country.

That is why I previously cosponsored something called Creating Transparency to Have Drug Rebates Unlocked.

I am going to go out and have all these town hall meetings, and I am going to hold that up.

Every drug should have a price that is available for all to see and creates equity.

Civica cannot get the big three PBMs to cover the drug.

It undermines the negotiation entirely.

The Pharmacy Benefit Manager Transparency Act of 2023 would make material improvements to the transparency of the U.S. health-care system.

What recommendations do you have for how and where to increase transparency throughout the prescription drug supply chain?

That means looking at pharmacy benefit manager practices with a thorough eye and taking any legislative steps necessary to ensure taxpayers and patients aren't getting a raw deal.

The average price that PBMs charge Medicare Part D plans for the exact same drug is over $3,000.

Taxpayers, seniors facing a 2,000-percent markup.